A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

ClinicalTrials.gov ID: NCT03523858

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03523858. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).

Study identification

NCT ID: NCT03523858
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 927 participants

Conditions and interventions

Conditions

Progressive Multiple Sclerosis (PMS)

Interventions

Ocrelizumab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 28, 2018 (Actual)
Primary completion: Oct 22, 2026 (Estimated)
Completion: Oct 22, 2026 (Estimated)
Last update posted: Jul 23, 2026

2018 – 2026

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 15

Facility	City	State	ZIP	Site status
MS Center of California	Laguna Hills	California	92653	—
SC3 Research Group, Inc	Pasadena	California	91105	—
University of California San Francisco	San Francisco	California	94158	—
University of South Florida	Tampa	Florida	33613	—
University of Chicago	Chicago	Illinois	60637-1470	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dragonfly Research, LLC	Wellesley	Massachusetts	02481	—
Wayne State University School of Medicine	Detroit	Michigan	48210	—
Washington University School of Medicine	St Louis	Missouri	63110	—
The MS Center of Northeastern New York	Latham	New York	12110	—
University of Cincinnati	Cincinnati	Ohio	45267	—
Neurology Clinic PC	Cordova	Tennessee	38018	—
Central Texas Neurology Consultants	Round Rock	Texas	78681	—
Lone Star Neurology of San Antonio	San Antonio	Texas	78258	—
Swedish Multiple Sclerosis Center	Seattle	Washington	98122	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 105 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03523858, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 23, 2026 · Synced Nov 15, 2026